Adalimumab at a dose of 0.8 mg/kg appears to be effective in treating children and adolescents with severe plaque psoriasis with no new safety risks, according to a recent phase III trial.
Timely and active treatment for bloodstream infections caused by carbapenemase-producing Enterobacteriaceae (CPE) is associated with lower mortality risk, according to a recent study. Moreover, only patients with a high risk of death appear to benefit from combination therapy.
The use of granulocyte colony stimulating-factor (G-CSF) is safe in patients with limited-stage small-cell lung cancer (SCLC) treated with chemoradiotherapy, according to a post hoc analysis of the phase III CONVERT trial presented at the European Lung Cancer Conference (ELCC) 2017.
Ensartinib, a small-molecule ALK tyrosine kinase inhibitor (TKI), has demonstrated intracranial response in patients with ALK-positive non-small-cell lung cancer (NSCLC) with central nervous system (CNS) metastases.
Treatment with osimertinib significantly improves symptoms in patients with advanced non-small-cell lung cancer (NSCLC), according to new data from the phase III AURA3 trial presented at the European Lung Cancer Conference (ELCC) 2017.
The use of uninterrupted dabigatran before, during, and after catheter ablation in patients with atrial fibrillation (AF) resulted in fewer major bleeding complications than uninterrupted warfarin, according to results of the RE-CIRCUIT* trial.